I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It's used to treat several types of ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International ...

TNF inhibitors were the first new group of biologic drugs for AS. They work by blocking a protein known as tumor necrosis factor, an inflammatory chemical that induces inflammation in the body.

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing p ...

PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.

Eligible Lancashire residents are being invited to book their spring Covid-19 vaccine, as the NHS warns the virus can still ...